News
HYTN approved to develop cannabis pharmaceuticals
Published on July 25, 2025 by Pat Bulmer
Photo: Contributed Kelowna-based HYTN Innovations has been approved to develop prescription drugs containing cannabis.
The company has received a Cannabis Drug Licence from Health Canada. The licence is required for any company intending to manufacture prescription drugs that contain cannabis for human use.
“This achievement enhances our capabilities, allowing us to strategically … participate directly in pharmaceutical drug development,” said Jason Broome, chief operations officer of HYTN, in a news release. “Securing the CDL is an important milestone in HYTN’s evolution.”
As a Good Manufacturing Practices-certified manufacturer, HYTN already exports medical marijuana.
“The newly issued CDL provides new and distinct regulatory pathways to the company, enabling the fabrication, packaging, labelling and distribution of prescription pharmaceutical products,” the release said.
The global pharmaceutical industry is already integrating cannabinoids, HYTN said, citing Epidiolex as an example.
“Epidiolex, an FDA- and EMA-approved prescription drug derived from cannabidiol (CBD), is authorized for the treatment of severe seizure disorders including Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
“According to its parent company, Jazz Pharmaceuticals, Epidiolex generated net product sales of USD $972.4 million in 2024, with a reported gross margin of 88.2% of net product sales, underscoring the clinical utility and commercial viability of cannabinoid-based pharmaceuticals.
Leave a comment on our Facebook page.
© Copyright 2025 Okanagan Z. | About the oz.
Report a Typo or Inaccuracy
We strive to avoid typos and inaccuracies. However, on occasion we make mistakes. We value your contributions and help in correcting them.